newsfilter
← Latest News
GlobeNewswire·

Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates

IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission Entered into a strategic collaboration with Bristol Myers Squibb to develop